Research progress of clinicopathology, diagnosis and treatment of invasive micropapillary carcinoma of the breast_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

WANG Yuechen , TANG Lu ,  XING Hua ,  ZHENG Zelin

Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, P. R. China;

Corresponding?author：

XING Hua, Email: xinghua1967@163.com; ZHENG Zelin, Email: zelinzheng@126.com

Keywords：

breast carcinoma; invasive micropapillary carcinoma; invasive ductal carcinoma; pathology

DOI：

10.7507/1007-9424.201812006

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the clinicopathological features, diagnosis and treatment of invasive micropapillary carcinoma (IMPC) of the breast.Method The relevant literatures at home and abroad in recent years about the clinical features, pathological features and diagnosis and treatment of IMPC were reviewed.Results IMPC is in low incidence and mostly in mixture. Because the clinical manifestations of IMPC and invasive ductal carcinoma of breast are basically similar, only the typical pathological features in pathological examination can confirm the diagnosis as " inside-out growth pattern” and " morula-like clusters of cancer cells surrounded by clear stromal spaces”.Conclusions IMPC is a special subtype of breast invasive carcinoma, which should be pay enough attention to it in clinic due to its unique microscopic morphology, high vessel invasiveness and high lymph node metastasis rate, high malignancy, poor prognosis and so on.

Citation： WANG Yuechen, TANG Lu, XING Hua, ZHENG Zelin. Research progress of clinicopathology, diagnosis and treatment of invasive micropapillary carcinoma of the breast. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(5): 636-640. doi: 10.7507/1007-9424.201812006 Copy

1.	Fisher ER, Palekar AS, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no.4). Ⅵ. Invasive papillary cancer. Am J Clin Pathol, 1980, 73(3): 313-322.
2.	Siriaunkgul S, Tavassoli FA. Invasive micropapillary carcinoma of the breast. Mod Pathol, 1993, 6(6): 660-662.
3.	皋嵐湘, 丁華野. WHO 乳腺腫瘤組織學分類 (2003). 臨床與實驗病理學雜志, 2004, 20(1): 3-4.
4.	張祥盛. WHO (2012) 乳腺腫瘤組織學分類. 診斷病理學雜志, 2012, 19(6): 477-478.
5.	Yang YL, Liu BB, Zhang X, et al. Invasive micropapillary carcinoma of the breast: An update. Arch Pathol Lab Med, 2016, 140(8): 799-805.
6.	姚建國, 劉穎. 浸潤性微乳頭狀癌的臨床病理研究現狀. 臨床與實驗病理學雜志, 2016, 32(12): 1379-1382.
7.	Ye FG, Xia C, Ma D, et al. Nomogram for predicting preoperative lymph node involvement in patients with invasive micropapillary carcinoma of breast: a SEER population-based study. BMC Cancer, 2018, 18(1): 1-9.
8.	Chen AC, Paulino AC, Schwartz MR, et al. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. Br J Cancer, 2014, 111(3): 619-622.
9.	Alsharif S, Daghistani R, Kambero?lu EA, et al. Mammographic, sonographic and MR imaging features of invasive micropapillary breast cancer. Eur J Radiol, 2014, 83(8): 1375-1380.
10.	蘇曉慧, 林青, 崔春曉, 等. 乳腺浸潤性微乳頭狀癌的影像學表現與免疫組化的相關性研究. 醫學影像學雜志, 2016, 26(2): 258-262.
11.	陳園園, 張嫣, 王霞, 等. 乳腺浸潤性微乳頭狀癌的 MRI 表現及臨床病理特點. 中國 CT 和 MRI 雜志, 2018, 16(4): 80-82.
12.	Lim HS, Kuzmiak CM, Jeong SI, et al. Invasive micropapillary carcinoma of the breast: MR imaging findings. Korean J Radiol, 2013, 14(4): 551-558.
13.	Baba S, Isoda T, Maruoka Y, et al. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. J Nucl Med, 2014, 55(5): 736-742.
14.	Yun SU, Choi BB, Shu KS, et al. Imaging findings of invasive micropapillary carcinoma of the breast. J Breast Cancer, 2012, 15(1): 57-64.
15.	內山瞳, 松井成明, 森下明博, 等. 乳腺原発 invasive micropapillary carcinoma の細胞學的検討. 日本臨床細胞學會雑誌, 2016, 55(3): 148-153.
16.	郭曉靜, 陳凌, 郎榮剛, 等. 乳腺浸潤性微乳頭狀癌的病理學特征與淋巴結轉移的關系. 中華病理學雜志, 2006, 35(1): 8-12.
17.	Kaya C, U?ak R, Bozkurt E, et al. The impact of micropapillary component ratio on the prognosis of patients with invasive micropapillary breast carcinoma. J Invest Surg, 2018, 29: 1-9.
18.	Collins K, Ricci A Jr. Micropapillary variant of mucinous breast carcinoma: A distinct subtype. Breast J, 2018, 24(3): 339-342.
19.	李曉艷, 劉芳芳, 李振華, 等. 乳腺具有微乳頭狀結構黏液癌的免疫表型及預后研究. 中國腫瘤臨床, 2015, 42(8): 411-415.
20.	付麗, 付笑影, 劉彤華. 乳腺浸潤性微乳頭狀癌的形態改變與生物學行為的關系. 中華病理學雜志, 2004, 33(1): 21-25.
21.	吳楠, 李瑩, 吳梓政, 等. 195 例乳腺浸潤性微乳頭狀癌臨床病理及預后分析. 中華普通外科雜志, 2017, 32(5): 397-401.
22.	Tang SL, Yang JQ, Du ZG, et al. Clinicopathologic study of invasive micropapillary carcinoma of the breast. Oncotarget, 2017, 8(26): 42455-42465.
23.	倪小健, 匡夏穎, 周平, 等. 基于多中心的中國乳腺浸潤性微乳頭狀癌的臨床特征分析. 中國臨床醫學, 2018, 25(4): 578-580.
24.	陳潔, 呂青, 王竹. 常用乳腺癌診治指南中對單純乳腺原位癌診治推薦的比較. 中國普外基礎與臨床雜志, 2017, 24(11): 1400-1407.
25.	Stewart RL, Caron JE, Gulbahce EH, et al. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features. Mod Pathol, 2017, 30(11): 1561-1566.
26.	Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med, 2018, 142(11): 1364-1382.
27.	Badyal RK, Bal A, Das A, et al. Invasive micropapillary carcinoma of the breast: immunophenotypic analysis and role of cell adhesion molecules (CD44 and E-cadherin) in nodal metastasis. Appl Immunohistochem Mol Morphol, 2016, 24(3): 151-158.
28.	Umeda T, Ishida M, Murata S, et al. Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component. Breast Cancer, 2016, 23(6): 869-875.
29.	Mercogliano MF, Inurrigarro G, De Martino M, et al. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer. BMC Cancer, 2017, 17(1): 895.
30.	Mercogliano MF, De Martino M, Venturutti L, et al. TNFα-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. Clin Cancer Res, 2017, 23(3): 636-648.
31.	Meng F, Liu B, Xie G, et al. Amplification and overexpression of PSCA at 8q24 in invasive micropapillary carcinoma of breast. Breast Cancer Res Treat, 2017, 166(2): 383-392.
32.	姜軍. 特殊類型乳腺癌分類及診治原則. 中國實用外科雜志, 2013, 33(3): 174-175.
33.	Doublier S, Belisario DC, Polimeni M, et al. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer, 2012, 12: 4.
34.	Wu SG, Zhang WW, Sun JY, et al. Postoperative radiotherapy for invasive micropapillary carcinoma of the breast: an analysis of surveillance, epidemiology, and end results database. Cancer Manag Res, 2017, (9): 453-459.
35.	Yu JI, Choi DH, Huh SJ, et al. Differences in prognostic factors and failure patterns between invasive micropapillary carcinoma and carcinoma with micropapillary component versus invasive ductal carcinoma of the breast: retrospective multicenter case–control study (KROG 13-06). Clin Breast Cancer, 2015, 15(5): 353-361.
36.	羅蒙, 許春景, 孫雨婷, 等. HER2 陽性乳腺癌的靶向治療及其耐藥機制. 實用腫瘤雜志, 2018, 33(3): 283-288.
37.	Lei S, Zhanhong C, Xiaojia W. ASCO 2018: recent advances in endocrine therapy for advanced breast cancer. Chin J Clin Oncol, 2018, 45(18): 919-921.
38.	華彬, 陸旭, 肖文政, 等. 乳腺浸潤性微乳頭狀癌與浸潤性導管癌預后比較的單中心回顧性病例配對研究. 中華外科雜志, 2018, 56(1): 56-60.
39.	Wu Y, Zhang N, Yang Q. The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis. BMC Cancer, 2017, 17(1): 839.

1. Fisher ER, Palekar AS, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no.4). Ⅵ. Invasive papillary cancer. Am J Clin Pathol, 1980, 73(3): 313-322.
2. Siriaunkgul S, Tavassoli FA. Invasive micropapillary carcinoma of the breast. Mod Pathol, 1993, 6(6): 660-662.
3. 皋嵐湘, 丁華野. WHO 乳腺腫瘤組織學分類 (2003). 臨床與實驗病理學雜志, 2004, 20(1): 3-4.
4. 張祥盛. WHO (2012) 乳腺腫瘤組織學分類. 診斷病理學雜志, 2012, 19(6): 477-478.
5. Yang YL, Liu BB, Zhang X, et al. Invasive micropapillary carcinoma of the breast: An update. Arch Pathol Lab Med, 2016, 140(8): 799-805.
6. 姚建國, 劉穎. 浸潤性微乳頭狀癌的臨床病理研究現狀. 臨床與實驗病理學雜志, 2016, 32(12): 1379-1382.
7. Ye FG, Xia C, Ma D, et al. Nomogram for predicting preoperative lymph node involvement in patients with invasive micropapillary carcinoma of breast: a SEER population-based study. BMC Cancer, 2018, 18(1): 1-9.
8. Chen AC, Paulino AC, Schwartz MR, et al. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. Br J Cancer, 2014, 111(3): 619-622.
9. Alsharif S, Daghistani R, Kambero?lu EA, et al. Mammographic, sonographic and MR imaging features of invasive micropapillary breast cancer. Eur J Radiol, 2014, 83(8): 1375-1380.
10. 蘇曉慧, 林青, 崔春曉, 等. 乳腺浸潤性微乳頭狀癌的影像學表現與免疫組化的相關性研究. 醫學影像學雜志, 2016, 26(2): 258-262.
11. 陳園園, 張嫣, 王霞, 等. 乳腺浸潤性微乳頭狀癌的 MRI 表現及臨床病理特點. 中國 CT 和 MRI 雜志, 2018, 16(4): 80-82.
12. Lim HS, Kuzmiak CM, Jeong SI, et al. Invasive micropapillary carcinoma of the breast: MR imaging findings. Korean J Radiol, 2013, 14(4): 551-558.
13. Baba S, Isoda T, Maruoka Y, et al. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. J Nucl Med, 2014, 55(5): 736-742.
14. Yun SU, Choi BB, Shu KS, et al. Imaging findings of invasive micropapillary carcinoma of the breast. J Breast Cancer, 2012, 15(1): 57-64.
15. 內山瞳, 松井成明, 森下明博, 等. 乳腺原発 invasive micropapillary carcinoma の細胞學的検討. 日本臨床細胞學會雑誌, 2016, 55(3): 148-153.
16. 郭曉靜, 陳凌, 郎榮剛, 等. 乳腺浸潤性微乳頭狀癌的病理學特征與淋巴結轉移的關系. 中華病理學雜志, 2006, 35(1): 8-12.
17. Kaya C, U?ak R, Bozkurt E, et al. The impact of micropapillary component ratio on the prognosis of patients with invasive micropapillary breast carcinoma. J Invest Surg, 2018, 29: 1-9.
18. Collins K, Ricci A Jr. Micropapillary variant of mucinous breast carcinoma: A distinct subtype. Breast J, 2018, 24(3): 339-342.
19. 李曉艷, 劉芳芳, 李振華, 等. 乳腺具有微乳頭狀結構黏液癌的免疫表型及預后研究. 中國腫瘤臨床, 2015, 42(8): 411-415.
20. 付麗, 付笑影, 劉彤華. 乳腺浸潤性微乳頭狀癌的形態改變與生物學行為的關系. 中華病理學雜志, 2004, 33(1): 21-25.
21. 吳楠, 李瑩, 吳梓政, 等. 195 例乳腺浸潤性微乳頭狀癌臨床病理及預后分析. 中華普通外科雜志, 2017, 32(5): 397-401.
22. Tang SL, Yang JQ, Du ZG, et al. Clinicopathologic study of invasive micropapillary carcinoma of the breast. Oncotarget, 2017, 8(26): 42455-42465.
23. 倪小健, 匡夏穎, 周平, 等. 基于多中心的中國乳腺浸潤性微乳頭狀癌的臨床特征分析. 中國臨床醫學, 2018, 25(4): 578-580.
24. 陳潔, 呂青, 王竹. 常用乳腺癌診治指南中對單純乳腺原位癌診治推薦的比較. 中國普外基礎與臨床雜志, 2017, 24(11): 1400-1407.
25. Stewart RL, Caron JE, Gulbahce EH, et al. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features. Mod Pathol, 2017, 30(11): 1561-1566.
26. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med, 2018, 142(11): 1364-1382.
27. Badyal RK, Bal A, Das A, et al. Invasive micropapillary carcinoma of the breast: immunophenotypic analysis and role of cell adhesion molecules (CD44 and E-cadherin) in nodal metastasis. Appl Immunohistochem Mol Morphol, 2016, 24(3): 151-158.
28. Umeda T, Ishida M, Murata S, et al. Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component. Breast Cancer, 2016, 23(6): 869-875.
29. Mercogliano MF, Inurrigarro G, De Martino M, et al. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer. BMC Cancer, 2017, 17(1): 895.
30. Mercogliano MF, De Martino M, Venturutti L, et al. TNFα-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. Clin Cancer Res, 2017, 23(3): 636-648.
31. Meng F, Liu B, Xie G, et al. Amplification and overexpression of PSCA at 8q24 in invasive micropapillary carcinoma of breast. Breast Cancer Res Treat, 2017, 166(2): 383-392.
32. 姜軍. 特殊類型乳腺癌分類及診治原則. 中國實用外科雜志, 2013, 33(3): 174-175.
33. Doublier S, Belisario DC, Polimeni M, et al. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer, 2012, 12: 4.
34. Wu SG, Zhang WW, Sun JY, et al. Postoperative radiotherapy for invasive micropapillary carcinoma of the breast: an analysis of surveillance, epidemiology, and end results database. Cancer Manag Res, 2017, (9): 453-459.
35. Yu JI, Choi DH, Huh SJ, et al. Differences in prognostic factors and failure patterns between invasive micropapillary carcinoma and carcinoma with micropapillary component versus invasive ductal carcinoma of the breast: retrospective multicenter case–control study (KROG 13-06). Clin Breast Cancer, 2015, 15(5): 353-361.
36. 羅蒙, 許春景, 孫雨婷, 等. HER2 陽性乳腺癌的靶向治療及其耐藥機制. 實用腫瘤雜志, 2018, 33(3): 283-288.
37. Lei S, Zhanhong C, Xiaojia W. ASCO 2018: recent advances in endocrine therapy for advanced breast cancer. Chin J Clin Oncol, 2018, 45(18): 919-921.
38. 華彬, 陸旭, 肖文政, 等. 乳腺浸潤性微乳頭狀癌與浸潤性導管癌預后比較的單中心回顧性病例配對研究. 中華外科雜志, 2018, 56(1): 56-60.
39. Wu Y, Zhang N, Yang Q. The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis. BMC Cancer, 2017, 17(1): 839.

Previous Article
Progress in the application of glutamine in nutritional support after hepatectomy

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress of clinicopathology, diagnosis and treatment of invasive micropapillary carcinoma of the breast

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content